Report of the NASPE/NHLBI round table on future research directions in atrial fibrillation

PACE - Pacing and Clinical Electrophysiology

Volumn 24, Issue 9 I, 2001, Pages 1435-1451

  Davis, C ^a   Saksena, S ^a   Domanski, M J ^a   Benjamin, E J ^a   Camm, A J ^a   Ezekowitz, M D ^a   Gersh, B J ^a   Jalife, J ^a   Naccarelli, G V ^a   Vlietstra, R E ^a   Wyse, D G ^a  

^a NASPE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; DIGOXIN; FLECAINIDE; IBUTILIDE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL; THROMBOPLASTIN;

CARDIOVERSION; CATHETER ABLATION; CONFERENCE PAPER; DEFIBRILLATION; GENE THERAPY; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HUMAN; MORTALITY; RISK FACTOR; STROKE; THROMBOSIS;

EID: 0034829041     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1460-9592.2001.01435.x     Document Type: Conference Paper

References (170)

1. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study
2. Prevalence of atrial fibrillation in elderly subjects (The Cardiovascular Health Study)
3. Atrial fibrillation and mortality in an elderly population
4. Prevalence of cardiovascular disease and diabetes mellitus in residents of Rochester, Minnesota
5. Prevalence, age distribution, and gender of patients with atrial fibrillation: Analysis and implications
6. Incidence of and risk factors for atrial fibrillation in older adults
7. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study
8. Secular trends in the prevalence of atrial fibrillation. The Framingham Study
9. National patterns of warfarin use in atrial fibrillation
10. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons
11. Arrhythmias and the "Holiday Heart": Alcohol-associated cardiac rhythm disorders
12. Identification of a genetic locus for familial atrial fibrillation
13. Is atrial fibrillation sometimes a genetic disease?
14. Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study
15. Atrial arrhythmias after cardiothoracic surgery
16. Supraventricular arrhythmia in patients having noncardiac surgery: Clinical correlates and effect on length of stay
17. Predictors of atrial fibrillation after coronary artery surgery: Current trends and impact on hospital resources
18. Meta-analysis of the effectiveness of prophylactic drug therapy in preventing supraventricular arrhythmia early after coronary artery bypass grafting
19. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery
20. Stroke severity in atrial fibrillation: The Framingham Study
21. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials
22. Mortality in an insured population with atrial fibrillation
23. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba Follow-Up Study
24. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study
25. Note sur les effets de la faradisation directe des ventricules du coeur chez le chien
26. Atrial fibrillation as a self-sustaining arrhythmia independent of focal discharge
27. A computer model of atrial fibrillation
28. Experimental evaluation of Moe's multiple wavelet hypothesis of atrial fibrillation
29. Quantitative assessment of the spatial organization of atrial fibrillation in the intact human heart
30. Spatiotemporal periodicity during atrial fibrillation in the isolated sheep heart
31. Mechanisms of atrial fibrillation: Mother rotors or multiple daughter wavelets, or both?
32. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins
33. Electrophysiology and endocardial mapping of induced atrial fibrillation in patients with spontaneous atrial fibrillation
34. Regional endocardial mapping of spontaneous and induced atrial fibrillation in patients with heart disease and refractory atrial fibrillation
35. Wave-front curvature as a cause of slow conduction and block in isolated cardiac muscle
36. Paradoxical improvement of impulse conduction in cardiac tissue by partial cellular uncoupling
37. Spatial and temporal organization during cardiac fibrillation
38. Simultaneous epicardial and endocardial activation sequence mapping in the isolated canine right atrium
39. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation
40. Two types of transient outward currents in adult human atrial cells
41. + current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation
42. Ionic determinants of atrial fibrillation and calcium channel abnormalities: Cause, caonsequence, or innocent bystander
43. Steady state and nonsteady-state action potentials in fibrillating canine atrium: Abnormal rate adaptation and its possible mechanisms
44. kur.d) in canine atrial myocytes
45. Restricted distribution of connexin40, a gap junction protein in mammalian heart
46. Tissue-specific determinants of anisotropic conduction velocity in canine atrial and ventricular myocardium
47. Cardiac tissue geometry as a determinant of unidirectional conduction block: Assessment of microscopic excitation spread by optical mapping in patterned cell cultures and in a computer model
48. Chronic rapid atrial pacing: Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation
49. Electrical remodeling in ischemia and infarction
50. Electrotonic modulation of the T wave and cardiac memory
51. Persistent T-wave changes after alteration of the ventricular activation sequence. New insights into cellular mechanisms of cardiac memory
52. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats
53. Tachycardia-induced changes in Na+ current in a chronic dog model of atrial fibrillation
54. Ultrarapid delayed rectifier current inactivation in human atrial myocytes: Properties and consequences
55. Biochemical mechanisms of reductions in calcium current caused by atrial tachycardia-induced electrical remodeling
56. Verapamil reduces tachycardia-induced electrical remodeling of the atria
57. Treatment with T-type calcium channel blocker prevents atrial fibrillation caused by tachycardia induced atrial remodeling
58. Cardiac function in genetically engineered mice with altered adrenergic receptor signaling
59. Remodeling of atrial cellular and ionic electrophysiology by congestive heart failure
60. Ionic mechanisms of action potential prolongation in ventricular myocytes from dogs with pacing-induced heart failure
61. Plasma norepinephrine as a guide to prognosis in patients with chronic heart failure
62. Chronic-adrenergic stimulation induces ionic remodeling in cultured adult guinea pig ventricular myocytes
63. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat
64. Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model
65. Catheter endocardial mapping of spontaneous termination of atrial fibrillation
66. Ionic targets for drug therapy and AF-induced electrical remodeling: Insights from a human atrial action potential model
67. Effects of class III antiarrhythmic drugs on transient outward and ultra-rapid delayed rectifier currents in human atrial myocytes
68. The protein C anticoagulant pathway
69. Cell mediated events that control blood coagulation and vascular injury
70. Tissue factor and hemostasis
71. The structural biology of expression and function of tissue factor
72. The role of tissue factor in the production of thrombin
73. A monoclonal antibody against rabbit tissue factor inhibits intravascular thrombosis
74. Selective cellular expression of tissue factor in human tissues: Implications of disorders of hemostasis and thrombosis
75. Modulation of tissue factor protein expression in experimental venous bypass grafts
76. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury
77. Tissue factor mediates prolonged procoagulant activity on the luminal surface of balloon-injured aortas in rabbits
78. Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion
79. Imaging in cerebrovascular diseases
80. Atrial fibrillation and mortality in an elderly population
81. Tissue plasminogen activation for acute ischemic stroke
82. Silent lacunar infarcts in elderly patients with chronic nonvalvular atrial fibrillation
83. Silent cerebral infarction in patients with non-rheumatic atrial fibrillation
84. Magnetic resonance imaging of acute stroke
85. Transcranial Doppler-detected microemboli in patients with acute stroke
86. Trancutaneous multielectrode basket catheter for endocardial mapping and ablation of ventricular tachycardia in the pig
87. Multielectrode basket catheter mapping for human atrial fibrillation
88. Guidance of radiofrequency endocardial ablation with real-time three-dimensional magnetic navigation system
89. Human left ventricular endocardial activation mapping using a novel noncontact catheter
90. Transcoronary venous radiofrequency catheter ablation of ventricular tachycardia
91. Nonfluoroscopic endocardial catheter mapping of atrial fibrillation
92. Guidance of linear lesion creation with a novel three dimensional intracardiac ultrasound ranging guidance system: A feasibility assessment
93. Loca Lisa: Electrical localization of endocardial electrodes
94. Interactive display and analysis of 3-D medical images
95. Optical mapping in a new guinea pig model of ventricular tachycardia reveals mechanisms for multiple wavelengths in a single reentrant circuit
96. The surgical treatment of atrial fibrillation. II. Intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation
97. A focal source of atrial fibrillation treated by discrete radiofrequency ablation
98. A catheter-based curative approach to atrial fibrillation in humans
99. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins
100. Clinical impact of electroanatomically guided catheter compartmentation of human atria in the treatment of paroxysmal atrial fibrillation
101. Chronic outcome of circumferential lesion creation in the pulmonary veins with a novel tandem balloon ablation catheter in dogs
102. Microwave catheter ablation using a clinical prototype system with a lateral fringe antenna design
103. Feasibility of cardiac cryoablation using a transvenous steerable electrode catheter
104. New applications of ultrasonography: Interventional ultrasound
105. Laser catheter ablation of chronic persistent atrial fibrillation
106. Successful catheter ablation of atrial fibrillation
107. Long-term prevention of vagal atrial arrhythmias by atrial pacing at 90/minute: Experience with 6 cases
108. DDD pacing: An effective treatment modality for recurrent atrial arrhythmias
109. Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome
110. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes
111. Atrial pacing peri-ablation for paroxysmal atrial fibrillation - Phase I
112. Prevention of recurrent atrial fibrillation with chronic dual site right atrial pacing
113. Long-term outcome of patients with drug-refractory atrial flutter and fibrillation after single and dual site right atrial pacing for arrhythmia prevention
114. Atrial tachyarrhythmias associated with high degree interatrial conduction block: Prevention by permanent atrial resynchronisation
115. Regional right and left atrial activation patterns during single and dual site atrial pacing in patients with atrial fibrillation
116. A new pacing algorithm for overdrive suppression of atrial fibrillation
117. Consistent atrial pacing algorithm to suppress recurrent paroxysmal atrial fibrillation: A randomized prospective cross over study
118. Marked reduction in internal atrial defibrillation thresholds with dual-current pathways and sequential shocks in humans
119. Clinical efficacy and safety of atrial defibrillation using biphasic shocks and current nonthoracotomy endocardial lead configurations
120. Is there a role for cardioversion of very chronic atrial fibrillation by transvenous atrial defibrillation
121. Atrioverter: An implantable device for the treatment of atrial fibrillation
122. Implantation of an arrhythmia management system for ventricular and supraventricular tachyarrhythmias
123. Worldwide clinical experience with the Model 7250 Jewel AF dual chamber arrhythmia management device
124. Clinical experience with a dual chamber implantable cardioverter defibrillator in patients with atrial fibrillation and flutter
125. Tolerability of internal low-energy shock strengths currently needed for endocardial atrial cardioversion
126. Interim results of a multicenter trial of temporary epicardial surgical wires used for the treatment of postoperative atrial fibrillation
127. Effects of high-frequency atrial pacing in atypical atrial flutter and atrial fibrillation
128. A prospective randomized comparison of high frequency burst pacing with antitachycardia ramp pacing for termination of induced atrial tachycardias
129. Internal atrial defibrillation: Effect on sinus and atrioventricular nodal function and implanted cardiac pacemakers
130. Likelihood of atrial fibrillation to sinus rhythm
131. Acute treatment of atrial fibrillation: Spontaneous conversion rates and cost of care
132. A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm
133. Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease
134. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: Results of a randomized, controlled study
135. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation
136. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation
137. Dofetilide in patients with congestive heart failure and left ventricular dysfunction
138. Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter
139. Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment
140. Possible atrial proarrhythmic effects of class IC antiarrhythmic drugs
141. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacologic treatment in patients with heart failure and chronic atrial fibrillation
142. Impact on ventricular function and quality of life of transcatheter ablation of the atrioventricular junction in chronic atrial fibrillation with a normal ventricular response
143. Quality of life and outcomes after radiofrequency his bundle catheter ablation and permanent pacemaker implantation: Impact of treatment in paroxysmal and established atrial fibrillation
144. Comparison of multiple biphasic and monophasic waveforms for internal cardioversion of atrial fibrillation in humans
145. A prospective hemodynamic evaluation of patients with chronic atrial fibrillation undergoing radiofrequency catheter ablation of the atrioventricular junction
146. Improvement in left ventricular systolic function after successful radiofrequency his bundle ablation for drug refractory, chronic atrial fibrillation and recurrent atrial flutter
147. Progression of permanent atrial fibrillation after atrioventricular junction ablation and dual-chamber pacemaker implantation in patients with paroxysmal atrial tachyarrhythmias
148. The Ablate and Pace Trial: A prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation
149. Comparisons of quality of life and cardiac performance after complete atrioventricular junction ablation and atrioventricular junction modification in patients with medically refractory atrial fibrillation
150. New method for terminating cardiac arrhythmias - Use of synchronised capacitor discharge
151. "Cardioversion" of atrial fibrillation. A report on the treatment of 65 episodes in 50 patients
152. Current management of atrial fibrillation
153. The optimal technique for electrical cardioversion of atrial fibrillation
154. Prospective assessment of the minimum energy needed for external electrical cardioversion of atrial fibrillation
155. Atrial fibrillation: Restoration and maintenance of sinus rhythm and indications for anticoagulation therapy
156. Factors determining success and energy requirements for cardioversion of atrial fibrillation
157. Echocardiographic and clinical predictors for outcome of elective cardioversion of atrial fibrillation
158. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter
159. Elective cardioversion: Influence of paddle-electrode location and size on success rates and energy requirements
160. Randomised comparison of electrode positions for cardioversion of atrial fibrillation
161. A randomized comparison of external and internal cardioversion of chronic atrial fibrillation
162. Low energy intracardiac cardioversion after failed conventional external cardioversion of atrial fibrillation
163. Cardioversion of nonrheumatic atrial fibrillation reduced thromboembolic complications with 4 weeks of precardioversion anticoagulation are related to atrial thrombus resolution
164. Internal cardioversion of atrial fibrillation: Marked reduction in defibrillation threshold with dual current pathways
165. Comparison of biphasic and monophasic waveforms in epicardial atrial defibrillation
166. Early out-of-hospital experience with an impedance compensating low energy biphasic waveform automatic external defibrillator
167. Atrial fibrillation follow-up investigation of rhythm management - The AFFIRM study design
168. Atrial fibrillation: Maintaining stability of sinus rhythm or ventricular rate control? The need for prospective data: The PIAF trial